Venture capital in biotech has had a great run over the past few years: funding going to private biotech companies is at historic highs, new venture funds are getting raised, and exits have been happening via robust IPO and M&A markets.  Yet, although it may come as a surprise to many, in the world of venture capital biotech remains a very minor player and has actually shrunk on a relative basis even during the latest boom.